141 related articles for article (PubMed ID: 35700821)
21. Molecular characterization of human multiple myeloma cell lines by integrative genomics: insights into the biology of the disease.
Lombardi L; Poretti G; Mattioli M; Fabris S; Agnelli L; Bicciato S; Kwee I; Rinaldi A; Ronchetti D; Verdelli D; Lambertenghi-Deliliers G; Bertoni F; Neri A
Genes Chromosomes Cancer; 2007 Mar; 46(3):226-38. PubMed ID: 17171682
[TBL] [Abstract][Full Text] [Related]
22. Long non-coding RNA ANGPTL1-3 promotes multiple myeloma bortezomib resistance by sponging miR-30a-3p to activate c-Maf expression.
Nian F; Zhu J; Chang H
Biochem Biophys Res Commun; 2019 Jul; 514(4):1140-1146. PubMed ID: 31103265
[TBL] [Abstract][Full Text] [Related]
23. The transmembrane protein TMEPAI induces myeloma cell apoptosis by promoting degradation of the c-Maf transcription factor.
Du Y; Liu Y; Xu Y; Juan J; Zhang Z; Xu Z; Cao B; Wang Q; Zeng Y; Mao X
J Biol Chem; 2018 Apr; 293(16):5847-5859. PubMed ID: 29467225
[TBL] [Abstract][Full Text] [Related]
24. Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma.
Chesi M; Bergsagel PL; Shonukan OO; Martelli ML; Brents LA; Chen T; Schröck E; Ried T; Kuehl WM
Blood; 1998 Jun; 91(12):4457-63. PubMed ID: 9616139
[TBL] [Abstract][Full Text] [Related]
25. A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression.
Annunziata CM; Hernandez L; Davis RE; Zingone A; Lamy L; Lam LT; Hurt EM; Shaffer AL; Kuehl WM; Staudt LM
Blood; 2011 Feb; 117(8):2396-404. PubMed ID: 21163924
[TBL] [Abstract][Full Text] [Related]
26. Ubiquitination of the transcription factor c-MAF is mediated by multiple lysine residues.
Chen G; Xu X; Tong J; Han K; Zhang Z; Tang J; Li S; Yang C; Li J; Cao B; Zhou H; Wu D; Moran MF; Mao X
Int J Biochem Cell Biol; 2014 Dec; 57():157-66. PubMed ID: 25448412
[TBL] [Abstract][Full Text] [Related]
27. Discovery of small molecule c-Maf inhibitors using molecular docking-based virtual screening, molecular dynamics simulation, and biological evaluation.
Hu Z; Zeng Y; Zhang Y; Zhang Q; Xu J; Liu L
Chem Biol Drug Des; 2024 Jan; 103(1):e14403. PubMed ID: 37984986
[TBL] [Abstract][Full Text] [Related]
28. N-cadherin-mediated interaction with multiple myeloma cells inhibits osteoblast differentiation.
Groen RW; de Rooij MF; Kocemba KA; Reijmers RM; de Haan-Kramer A; Overdijk MB; Aalders L; Rozemuller H; Martens AC; Bergsagel PL; Kersten MJ; Pals ST; Spaargaren M
Haematologica; 2011 Nov; 96(11):1653-61. PubMed ID: 21828122
[TBL] [Abstract][Full Text] [Related]
29. Identification of primary MAFB target genes in multiple myeloma.
van Stralen E; van de Wetering M; Agnelli L; Neri A; Clevers HC; Bast BJ
Exp Hematol; 2009 Jan; 37(1):78-86. PubMed ID: 19013005
[TBL] [Abstract][Full Text] [Related]
30. TACI expression is associated with a mature bone marrow plasma cell signature and C-MAF overexpression in human myeloma cell lines.
Moreaux J; Hose D; Jourdan M; Reme T; Hundemer M; Moos M; Robert N; Moine P; De Vos J; Goldschmidt H; Klein B
Haematologica; 2007 Jun; 92(6):803-11. PubMed ID: 17550853
[TBL] [Abstract][Full Text] [Related]
31. The Role of AP-1 Transcription Factors in Plasma Cell Biology and Multiple Myeloma Pathophysiology.
Fan F; Podar K
Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34066181
[TBL] [Abstract][Full Text] [Related]
32. Regulation of the MAFF transcription factor by proinflammatory cytokines in myometrial cells.
Massrieh W; Derjuga A; Doualla-Bell F; Ku CY; Sanborn BM; Blank V
Biol Reprod; 2006 Apr; 74(4):699-705. PubMed ID: 16371591
[TBL] [Abstract][Full Text] [Related]
33. Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma.
Gupta VA; Matulis SM; Conage-Pough JE; Nooka AK; Kaufman JL; Lonial S; Boise LH
Blood; 2017 Apr; 129(14):1969-1979. PubMed ID: 28151428
[TBL] [Abstract][Full Text] [Related]
34. Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells.
Noll JE; Williams SA; Tong CM; Wang H; Quach JM; Purton LE; Pilkington K; To LB; Evdokiou A; Gronthos S; Zannettino AC
Haematologica; 2014 Jan; 99(1):163-71. PubMed ID: 23935020
[TBL] [Abstract][Full Text] [Related]
35. Circular RNA cia-MAF drives self-renewal and metastasis of liver tumor-initiating cells via transcription factor MAFF.
Chen Z; Lu T; Huang L; Wang Z; Yan Z; Guan Y; Hu W; Fan Z; Zhu P
J Clin Invest; 2021 Oct; 131(19):. PubMed ID: 34403373
[TBL] [Abstract][Full Text] [Related]
36. MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma.
Qiang YW; Ye S; Chen Y; Buros AF; Edmonson R; van Rhee F; Barlogie B; Epstein J; Morgan GJ; Davies FE
Blood; 2016 Dec; 128(25):2919-2930. PubMed ID: 27793878
[TBL] [Abstract][Full Text] [Related]
37. Multiple myeloma: biology of the disease.
Mahindra A; Hideshima T; Anderson KC
Blood Rev; 2010 Nov; 24 Suppl 1():S5-11. PubMed ID: 21126636
[TBL] [Abstract][Full Text] [Related]
38. Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment.
Lam C; Ferguson ID; Mariano MC; Lin YT; Murnane M; Liu H; Smith GA; Wong SW; Taunton J; Liu JO; Mitsiades CS; Hann BC; Aftab BT; Wiita AP
Haematologica; 2018 Jul; 103(7):1218-1228. PubMed ID: 29622655
[TBL] [Abstract][Full Text] [Related]
39. Multiple Myeloma: Molecular Pathogenesis and Disease Evolution.
Heider M; Nickel K; Högner M; Bassermann F
Oncol Res Treat; 2021; 44(12):672-681. PubMed ID: 34749378
[TBL] [Abstract][Full Text] [Related]
40. Atypical IgM multiple myeloma with deletion of c-MAF.
Juárez Salcedo LM; López Rubio M; Gil Fernández JJ; Garcia-Suarez J; Magro E; Arranz E; Gutiérrez Jomarrón I; Marcellini Antonio S; Blasco A; Burgaleta C
Int J Lab Hematol; 2015 Oct; 37(5):686-9. PubMed ID: 25996654
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
